Medical device giant — pacemakers, TAVR, insulin pumps, surgical robotics. Customer of the toll-road infrastructure stack (Measure, Manufacture, Package & Deliver). Diabetes spin-off is a catalyst for re-rating the core cardio/neuro business.
Conviction●●●○○3 of 5
Research target—Snapshot target
Thesis statusACTIVE_RESEARCHLast reviewed Not reviewed
Market cap$106.49BSnapshot value
Diabetes business spin-off (timing TBD), Hugo RAS surgical robotics ramp, PulseSelect PFA ablation adoption, Evolut TAVR low-risk label expansion
1. Diabetes spin-off delayed/cancelled. 2. Hugo RAS fails to gain share vs Da Vinci. 3. TAVR market share loss to Edwards Sapien. 4. PFA commoditization (BSX, JNJ, ABT competing). 5. Medtech procedure volume recession.
Low retail interest despite dividend and spin-off catalyst. Institutional-heavy ownership (89%).
Snapshot · Not reviewedNo positioning snapshot available.
Snapshot · Not reviewed